{
  "meta": {
    "id": "test9",
    "title": "Gastrointestinal System",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "Mechanism of action of an aprepitant is?",
      "options": [
        {
          "label": "A",
          "text": "RANK ligand inhibitor",
          "correct": false
        },
        {
          "label": "B",
          "text": "NMDA antagonist",
          "correct": false
        },
        {
          "label": "C",
          "text": "NK 1 receptor antagonist",
          "correct": true
        },
        {
          "label": "D",
          "text": "5 HT3 antagonist",
          "correct": false
        }
      ],
      "correct_answer": "C. NK 1 receptor antagonist",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) NK 1 receptor antagonist</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. RANK ligand inhibitor: Incorrect because RANK ligand inhibitors like denosumab are used to treat osteoporosis and bone metastases , not nausea and vomiting. These drugs inhibit RANK ligand, a protein essential for the formation and survival of osteoclasts, which are involved in bone resorption.</li><li>\u2022 Option A. RANK ligand inhibitor:</li><li>\u2022 Incorrect</li><li>\u2022 RANK ligand inhibitors</li><li>\u2022 denosumab</li><li>\u2022 treat osteoporosis</li><li>\u2022 bone</li><li>\u2022 metastases</li><li>\u2022 inhibit RANK ligand,</li><li>\u2022 formation and survival of</li><li>\u2022 osteoclasts,</li><li>\u2022 bone resorption.</li><li>\u2022 Option B. NMDA antagonist: Incorrect as NMDA antagonists, such as memantine , target cognitive decline in Alzheimer\u2019s disease rather than nausea and vomiting.</li><li>\u2022 Option B. NMDA antagonist:</li><li>\u2022 Incorrect</li><li>\u2022 NMDA antagonists,</li><li>\u2022 memantine</li><li>\u2022 target cognitive</li><li>\u2022 Alzheimer\u2019s disease</li><li>\u2022 nausea and vomiting.</li><li>\u2022 Option D. 5 HT3 antagonist: Incorrect because 5-HT3 antagonists, like ondansetron and granisetron , also prevent nausea and vomiting in settings like chemotherapy and post-operation but function by blocking 5-HT3 receptors on the vagus nerve and in the central nervous system , not NK1 receptors.</li><li>\u2022 Option D. 5 HT3 antagonist:</li><li>\u2022 Incorrect</li><li>\u2022 5-HT3 antagonists,</li><li>\u2022 ondansetron and granisetron</li><li>\u2022 prevent nausea and</li><li>\u2022 vomiting</li><li>\u2022 chemotherapy and post-operation</li><li>\u2022 blocking 5-HT3 receptors</li><li>\u2022 vagus nerve</li><li>\u2022 central nervous system</li><li>\u2022 not NK1 receptors.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 NK1 receptor antagonist used primarily to prevent delayed chemotherapy-induced nausea and vomiting by inhibiting the action of substance P on NK1 receptors.</li><li>\u27a4 NK1 receptor antagonist</li><li>\u27a4 prevent delayed chemotherapy-induced nausea and vomiting</li><li>\u27a4 inhibiting</li><li>\u27a4 substance P on NK1 receptors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2135872c",
      "audio": ""
    },
    {
      "text": "Despite their short half-lives (2 hrs), proton pump inhibitors (PPIs) cause a prolonged suppression of acid secretion (up to 48 hrs) because?",
      "options": [
        {
          "label": "A",
          "text": "They are pro-drugs and undergo activation gradually",
          "correct": false
        },
        {
          "label": "B",
          "text": "From stomach, these quickly reach the parietal cells and enter acid secretory canaliculi and stay there, blocking the secretion of acid for a long time",
          "correct": false
        },
        {
          "label": "C",
          "text": "They irreversible inhibit the proton pump molecule",
          "correct": true
        },
        {
          "label": "D",
          "text": "They are available as enteric coated capsules, from which drug is gradually released",
          "correct": false
        }
      ],
      "correct_answer": "C. They irreversible inhibit the proton pump molecule",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) They irreversible inhibit the proton pump molecule</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. They are pro-drugs and undergo activation gradually: Incorrect because while PPIs are indeed prodrugs that are activated within the acidic environment of the parietal cells , the gradual activation does not directly contribute to the prolonged acid suppression . The prolongation comes from the irreversible inhibition of the pumps.</li><li>\u2022 Option A. They are pro-drugs and undergo activation gradually:</li><li>\u2022 Incorrect</li><li>\u2022 PPIs</li><li>\u2022 prodrugs</li><li>\u2022 within</li><li>\u2022 parietal cells</li><li>\u2022 gradual activation does not</li><li>\u2022 prolonged acid</li><li>\u2022 suppression</li><li>\u2022 irreversible inhibition of the pumps.</li><li>\u2022 Option B. From stomach, these quickly reach the parietal cells and enter acid secretory canaliculi and stay there, blocking the secretion of acid for a long time: Incorrect because PPIs do not travel directly from the stomach to the parietal cells. They must first be absorbed from the intestine and then distributed to the parietal cells via the bloodstream.</li><li>\u2022 Option B. From stomach, these quickly reach the parietal cells and enter acid secretory canaliculi and stay there, blocking the secretion of acid for a long time:</li><li>\u2022 Incorrect</li><li>\u2022 PPIs do not</li><li>\u2022 stomach to the parietal cells.</li><li>\u2022 absorbed from the intestine</li><li>\u2022 distributed to the parietal cells</li><li>\u2022 bloodstream.</li><li>\u2022 Option D. They are available as enteric coated capsules, from which drug is gradually released: Incorrect as the enteric coating only serves to protect the drug from gastric acid degradation rather than prolonging its action at the site of the proton pumps.</li><li>\u2022 Option D. They are available as enteric coated capsules, from which drug is gradually released:</li><li>\u2022 Incorrect</li><li>\u2022 enteric coating</li><li>\u2022 protect the drug</li><li>\u2022 gastric acid degradation</li><li>\u2022 prolonging its action</li><li>\u2022 site of the proton pumps.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Proton pump inhibitor s cause prolonged acid suppression by irreversibly binding to and inactivating the proton pumps in the stomach, and acid secretion only resumes once new pumps are synthesized and active.</li><li>\u27a4 Proton pump inhibitor</li><li>\u27a4 prolonged acid suppression</li><li>\u27a4 irreversibly binding to</li><li>\u27a4 inactivating the proton pumps</li><li>\u27a4 acid secretion</li><li>\u27a4 resumes</li><li>\u27a4 new pumps are synthesized and active.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2be48497",
      "audio": ""
    },
    {
      "text": "A patient of peptic ulcer was prescribed ranitidine and sucralfate in the morning hours. Why is this combination incorrect?",
      "options": [
        {
          "label": "A",
          "text": "Ranitidine combines with sucralfate and prevents its action",
          "correct": false
        },
        {
          "label": "B",
          "text": "Combination of these two drugs produces serious side effects like agranulocytosis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ranitidine increases the gastric pH so sucralfate is not able to act",
          "correct": true
        },
        {
          "label": "D",
          "text": "Sucralfate inhibits the absorption of ranitidine",
          "correct": false
        }
      ],
      "correct_answer": "C. Ranitidine increases the gastric pH so sucralfate is not able to act",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Ranitidine increases the gastric pH so sucralfate is not able to act</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Ranitidine combines with sucralfate and prevents its action: Incorrect because ranitidine does not chemically combine with sucralfate ; the issue is the pH environment alteration.</li><li>\u2022 Option A. Ranitidine combines with sucralfate and prevents its action:</li><li>\u2022 Incorrect</li><li>\u2022 ranitidine does not</li><li>\u2022 sucralfate</li><li>\u2022 pH environment alteration.</li><li>\u2022 Option B. Combination of these two drugs produces serious side effects like agranulocytosis: Incorrect as there is no evidence to suggest that agranulocytosis is a common side effect of combining these two drugs.</li><li>\u2022 Option B. Combination of these two drugs produces serious side effects like agranulocytosis:</li><li>\u2022 no</li><li>\u2022 agranulocytosis</li><li>\u2022 common side effect</li><li>\u2022 two drugs.</li><li>\u2022 Option D. Sucralfate inhibits the absorption of ranitidine: Incorrect because sucralfate does not affect the absorption of ranitidine; its primary interaction is with the gastric pH affecting its own mechanism of action.</li><li>\u2022 Option D. Sucralfate inhibits the absorption of ranitidine:</li><li>\u2022 Incorrect</li><li>\u2022 sucralfate does not</li><li>\u2022 absorption of ranitidine;</li><li>\u2022 gastric pH</li><li>\u2022 own mechanism of action.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Sucralfate needs an acidic environment to be effective. Co-administration with ranitidine, which raises gastric pH, can impair the effectiveness of sucralfate in treating ulcers.</li><li>\u27a4 Sucralfate</li><li>\u27a4 acidic environment</li><li>\u27a4 effective.</li><li>\u27a4 Co-administration</li><li>\u27a4 ranitidine,</li><li>\u27a4 raises gastric pH,</li><li>\u27a4 impair</li><li>\u27a4 effectiveness of sucralfate</li><li>\u27a4 ulcers.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ae38d8a9",
      "audio": ""
    },
    {
      "text": "All of the following adverse effects are associated with the use of proton pump inhibitors except?",
      "options": [
        {
          "label": "A",
          "text": "Community acquired pneumonia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Clostridium difficile infection",
          "correct": false
        },
        {
          "label": "C",
          "text": "Osteoporosis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypothyroidism",
          "correct": true
        }
      ],
      "correct_answer": "D. Hypothyroidism",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Hypothyroidism</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Community acquired pneumonia: Correctly associated with PPIs. Some studies have indicated an increased risk of pneumonia, particularly in vulnerable groups such as the elderly or those with existing respiratory conditions , possibly due to alterations in stomach pH affecting gut and respiratory flora.</li><li>\u2022 Option A. Community acquired pneumonia:</li><li>\u2022 PPIs.</li><li>\u2022 increased risk of</li><li>\u2022 pneumonia,</li><li>\u2022 elderly</li><li>\u2022 existing respiratory conditions</li><li>\u2022 alterations in stomach pH</li><li>\u2022 gut and respiratory flora.</li><li>\u2022 Option B. Clostridium difficile infection: Correctly associated with PPIs. The reduction in gastric acidity can lead to an environment more conducive to the growth of Clostridium difficile , potentially resulting in severe and life-threatening infections.</li><li>\u2022 Option B. Clostridium difficile infection:</li><li>\u2022 Correctly</li><li>\u2022 PPIs.</li><li>\u2022 reduction in gastric acidity</li><li>\u2022 more conducive</li><li>\u2022 growth of Clostridium difficile</li><li>\u2022 severe and life-threatening infections.</li><li>\u2022 Option C. Osteoporosis: Correctly associated with PPIs . Chronic use of PPIs may impact calcium absorption and bone metabolism, leading to an increased risk of osteoporosis and related fractures, especially in populations at risk like postmenopausal women and the elderly.</li><li>\u2022 Option C. Osteoporosis:</li><li>\u2022 Correctly</li><li>\u2022 PPIs</li><li>\u2022 Chronic</li><li>\u2022 PPIs</li><li>\u2022 impact calcium absorption</li><li>\u2022 bone metabolism,</li><li>\u2022 increased risk of osteoporosis</li><li>\u2022 fractures,</li><li>\u2022 risk like postmenopausal women</li><li>\u2022 elderly.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While PPIs are linked to several significant adverse effects such as increased risks of community-acquired pneumonia, Clostridium difficile infections , and osteoporosis , they are not associated with causing or worsening hypothyroidism.</li><li>\u27a4 PPIs are linked</li><li>\u27a4 adverse effects</li><li>\u27a4 increased risks of community-acquired pneumonia,</li><li>\u27a4 Clostridium</li><li>\u27a4 difficile infections</li><li>\u27a4 osteoporosis</li><li>\u27a4 not</li><li>\u27a4 causing or worsening hypothyroidism.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2a57ab05",
      "audio": ""
    },
    {
      "text": "Which of the following drugs have least affinity for CYP3A4?",
      "options": [
        {
          "label": "A",
          "text": "Omeprazole",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lansoprazole",
          "correct": false
        },
        {
          "label": "C",
          "text": "Esomeprazole",
          "correct": false
        },
        {
          "label": "D",
          "text": "Rabeprazole",
          "correct": true
        }
      ],
      "correct_answer": "D. Rabeprazole",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Rabeprazole</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Omeprazole: Incorrect because Omeprazole is extensively metabolized by CYP3A4, making it more likely to interact with other drugs metabolized by this enzyme.</li><li>\u2022 Option A. Omeprazole:</li><li>\u2022 Incorrect</li><li>\u2022 Omeprazole</li><li>\u2022 extensively metabolized by CYP3A4,</li><li>\u2022 more likely</li><li>\u2022 interact</li><li>\u2022 other drugs</li><li>\u2022 Option B. Lansoprazole: Incorrect as Lansoprazole also has significant metabolism via CYP3A4, similar to omeprazole, which increases its potential for drug interactions.</li><li>\u2022 Option B. Lansoprazole:</li><li>\u2022 Incorrect</li><li>\u2022 Lansoprazole</li><li>\u2022 CYP3A4,</li><li>\u2022 omeprazole,</li><li>\u2022 increases its potential</li><li>\u2022 drug interactions.</li><li>\u2022 Option C. Esomeprazole: Incorrect because Esomeprazole, the S-isomer of omeprazole, is extensively metabolized by CYP3A4 , thus having a higher affinity for this enzyme compared to rabeprazole.</li><li>\u2022 Option C. Esomeprazole:</li><li>\u2022 Incorrect</li><li>\u2022 Esomeprazole,</li><li>\u2022 S-isomer of omeprazole,</li><li>\u2022 metabolized by CYP3A4</li><li>\u2022 higher affinity for this enzyme</li><li>\u2022 rabeprazole.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Rabeprazole has the least affinity for the enzyme CYP3A4 among the listed PPIs , potentially leading to fewer drug interactions related to metabolism by this pathway.</li><li>\u27a4 Rabeprazole</li><li>\u27a4 least affinity</li><li>\u27a4 CYP3A4</li><li>\u27a4 listed PPIs</li><li>\u27a4 fewer drug interactions</li><li>\u27a4 metabolism</li><li>\u27a4 this pathway.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ec047f41",
      "audio": ""
    },
    {
      "text": "A 30-year-old pregnant woman has a history of rheumatoid arthritis which has been managed successfully with NSAIDs. However, she has recently visited her general practitioner complaining of burning epigastric pain worsened by food intake. Which of the following ulcer medication is most likely contraindicated in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Famotidine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Omeprazole",
          "correct": false
        },
        {
          "label": "C",
          "text": "Misoprostol",
          "correct": true
        },
        {
          "label": "D",
          "text": "Ranitidine",
          "correct": false
        }
      ],
      "correct_answer": "C. Misoprostol",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Misoprostol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Famotidine: Incorrect as Famotidine, an H2 receptor antagonist, is generally considered safe for use during pregnancy . It works by reducing stomach acid and is not known to harm the fetus.</li><li>\u2022 Option A. Famotidine:</li><li>\u2022 Incorrect</li><li>\u2022 H2 receptor antagonist,</li><li>\u2022 considered safe</li><li>\u2022 during pregnancy</li><li>\u2022 reducing stomach acid</li><li>\u2022 not</li><li>\u2022 harm the fetus.</li><li>\u2022 Option B. Omeprazole: Incorrect because Omeprazole , a proton pump inhibitor , is also used to manage ulcer symptoms by reducing acid production. While its use in pregnancy should be cautious, it is not specifically contraindicated like Misoprostol.</li><li>\u2022 Option B. Omeprazole:</li><li>\u2022 Incorrect</li><li>\u2022 Omeprazole</li><li>\u2022 proton pump inhibitor</li><li>\u2022 used</li><li>\u2022 reducing</li><li>\u2022 acid production.</li><li>\u2022 use in pregnancy</li><li>\u2022 cautious,</li><li>\u2022 not</li><li>\u2022 contraindicated</li><li>\u2022 Misoprostol.</li><li>\u2022 Option D. Ranitidine: Incorrect as Ranitidine, another H2 receptor antagonist, is typically safe for use during pregnancy. It works similarly to Famotidine by reducing gastric acid and is not associated with significant risks to the developing fetus.</li><li>\u2022 Option D. Ranitidine:</li><li>\u2022 Incorrect</li><li>\u2022 H2 receptor antagonist,</li><li>\u2022 safe</li><li>\u2022 during pregnancy.</li><li>\u2022 similarly to Famotidine</li><li>\u2022 reducing gastric acid</li><li>\u2022 not</li><li>\u2022 risks</li><li>\u2022 developing fetus.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Misoprostol is contraindicated in pregnant patients due to its potential to induce uterine contractions and risk causing abortion.</li><li>\u27a4 Misoprostol</li><li>\u27a4 contraindicated in pregnant</li><li>\u27a4 its potential</li><li>\u27a4 induce uterine contractions</li><li>\u27a4 risk</li><li>\u27a4 abortion.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "958a098d",
      "audio": ""
    },
    {
      "text": "Drug implicated in prolonging QT interval is?",
      "options": [
        {
          "label": "A",
          "text": "Domperidone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Metoclopramide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cisapride",
          "correct": true
        },
        {
          "label": "D",
          "text": "Omeprazole",
          "correct": false
        }
      ],
      "correct_answer": "C. Cisapride",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/screenshot-2024-05-03-095836.png"
      ],
      "explanation": "<p><strong>Ans. C) Cisapride</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Domperidone: Incorrect because while Domperidone does have some cardiac risk , it is more specifically associated with an increased risk of serious ventricular arrhythmias and sudden cardiac death rather than QT prolongation.</li><li>\u2022 Option A. Domperidone:</li><li>\u2022 Incorrect</li><li>\u2022 Domperidone</li><li>\u2022 cardiac risk</li><li>\u2022 increased risk of serious ventricular arrhythmias</li><li>\u2022 sudden cardiac death</li><li>\u2022 Option B. Metoclopramide: Incorrect as Metoclopramide, another prokinetic agent, primarily affects dopamine receptors and has not been commonly associated with QT prolongation.</li><li>\u2022 Option B. Metoclopramide:</li><li>\u2022 Incorrect</li><li>\u2022 prokinetic agent,</li><li>\u2022 dopamine receptors</li><li>\u2022 not</li><li>\u2022 QT prolongation.</li><li>\u2022 Option D. Omeprazole: Incorrect because Omeprazole, a proton pump inhibitor, does not typically cause QT prolongation as part of its side effect profile.</li><li>\u2022 Option D. Omeprazole:</li><li>\u2022 Incorrect</li><li>\u2022 proton pump inhibitor,</li><li>\u2022 does not</li><li>\u2022 QT prolongation</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Cisapride is associated with QT interval prolongation and can lead to torsades de pointes , particularly at high concentrations or when combined with other drugs that inhibit its metabolism.</li><li>\u27a4 Cisapride</li><li>\u27a4 QT interval prolongation</li><li>\u27a4 torsades de pointes</li><li>\u27a4 high concentrations</li><li>\u27a4 combined with other drugs</li><li>\u27a4 inhibit its metabolism.</li><li>\u27a4 Important drugs causing QT prolongation</li><li>\u27a4 Important drugs causing QT prolongation</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "319d2ac5",
      "audio": ""
    },
    {
      "text": "All the following statements about treatment of diarrhea are correct except?",
      "options": [
        {
          "label": "A",
          "text": "Opioids delay passage of gut contents by reducing peristalsis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Loperamide is an opioid with anti-motility action",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anti-motility drugs are best drugs for infective diarrhea",
          "correct": true
        },
        {
          "label": "D",
          "text": "Diphenoxylate overdose can cause respiratory depression",
          "correct": false
        }
      ],
      "correct_answer": "C. Anti-motility drugs are best drugs for infective diarrhea",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Anti-motility drugs are best drugs for infective diarrhea</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Opioids delay passage of gut contents by reducing peristalsis: Correct , opioids inhibit gastrointestinal motility, leading to slower transit times and more water absorption , which can help alleviate diarrhea symptoms.</li><li>\u2022 Option A. Opioids delay passage of gut contents by reducing peristalsis:</li><li>\u2022 Correct</li><li>\u2022 inhibit gastrointestinal motility,</li><li>\u2022 slower transit</li><li>\u2022 more water absorption</li><li>\u2022 alleviate diarrhea symptoms.</li><li>\u2022 Option B. Loperamide is an opioid with anti-motility action: Correct , loperamide acts on opioid receptors in the gastrointestinal tract to reduce motility and increase the absorption of fluids, making it effective in managing diarrhea.</li><li>\u2022 Option B. Loperamide is an opioid with anti-motility action:</li><li>\u2022 Correct</li><li>\u2022 loperamide</li><li>\u2022 opioid receptors</li><li>\u2022 gastrointestinal</li><li>\u2022 tract</li><li>\u2022 reduce motility</li><li>\u2022 increase the absorption of fluids,</li><li>\u2022 Option D. Diphenoxylate overdose can cause respiratory depression: Correct, diphenoxylate is an opioid and, like other opioids, can cause significant respiratory depression if overdosed.</li><li>\u2022 Option D. Diphenoxylate overdose can cause respiratory depression:</li><li>\u2022 Correct,</li><li>\u2022 diphenoxylate</li><li>\u2022 opioid</li><li>\u2022 respiratory depression</li><li>\u2022 overdosed.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While anti-motility drugs are effective in managing non-infective diarrhea, they are not recommended for treating infective diarrhea due to the risk of prolonging the presence of pathogens in the gastrointestinal tract.</li><li>\u27a4 anti-motility drugs</li><li>\u27a4 effective</li><li>\u27a4 non-infective diarrhea,</li><li>\u27a4 not</li><li>\u27a4 treating infective diarrhea</li><li>\u27a4 risk</li><li>\u27a4 presence of pathogens</li><li>\u27a4 gastrointestinal tract.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2c139980",
      "audio": ""
    },
    {
      "text": "False statement about racecadotril is?",
      "options": [
        {
          "label": "A",
          "text": "It is a pro-drug that is converted to peripherally acting enkephalinase inhibitor",
          "correct": false
        },
        {
          "label": "B",
          "text": "It is a drug used in treatment of constipation",
          "correct": true
        },
        {
          "label": "C",
          "text": "It is metabolized by liver",
          "correct": false
        },
        {
          "label": "D",
          "text": "It has anti- secretory action in GIT",
          "correct": false
        }
      ],
      "correct_answer": "B. It is a drug used in treatment of constipation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) It is drug used in constipation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It is a pro-drug that is converted to peripherally acting enkephalinase inhibitor: Correct , racecadotril is a pro-drug that is metabolized into thiorphan , which acts peripherally to inhibit enkephalinase , thus prolonging the action of naturally occurring opioids that decrease gut motility.</li><li>\u2022 Option A. It is a pro-drug that is converted to peripherally acting enkephalinase inhibitor:</li><li>\u2022 Correct</li><li>\u2022 racecadotril</li><li>\u2022 pro-drug</li><li>\u2022 metabolized into thiorphan</li><li>\u2022 peripherally</li><li>\u2022 inhibit enkephalinase</li><li>\u2022 prolonging the action</li><li>\u2022 naturally occurring</li><li>\u2022 opioids</li><li>\u2022 decrease gut motility.</li><li>\u2022 Option C. It is metabolized by liver: Correct, racecadotril undergoes metabolic processes in the liver, converting it into its active form.</li><li>\u2022 Option C. It is metabolized by liver:</li><li>\u2022 Correct, racecadotril</li><li>\u2022 metabolic</li><li>\u2022 liver,</li><li>\u2022 its active</li><li>\u2022 form.</li><li>\u2022 Option D. It has anti-secretory action in GIT: Correct, by inhibiting the breakdown of enkephalins, racecadotril enhances their natural anti-secretory effects in the gastrointestinal tract, which is beneficial in treating diarrhea.</li><li>\u2022 Option D. It has anti-secretory action in GIT:</li><li>\u2022 Correct,</li><li>\u2022 inhibiting the breakdown of enkephalins,</li><li>\u2022 racecadotril</li><li>\u2022 natural</li><li>\u2022 anti-secretory effects in the gastrointestinal tract,</li><li>\u2022 beneficial</li><li>\u2022 treating diarrhea.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Racecadotril is indicated for the treatment of acute diarrhea and works by reducing gastrointestinal secretion; it is not used for constipation and indeed would be contraindicated in such cases.</li><li>\u27a4 Racecadotril</li><li>\u27a4 indicated</li><li>\u27a4 acute diarrhea</li><li>\u27a4 reducing gastrointestinal secretion;</li><li>\u27a4 not</li><li>\u27a4 constipation</li><li>\u27a4 indeed</li><li>\u27a4 contraindicated</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d9442ff6",
      "audio": ""
    },
    {
      "text": "Racecadotril is used for?",
      "options": [
        {
          "label": "A",
          "text": "Chronic diarrhea",
          "correct": false
        },
        {
          "label": "B",
          "text": "Acute secretory diarrhea",
          "correct": true
        },
        {
          "label": "C",
          "text": "Chronic constipation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Diabetic gastroparesis",
          "correct": false
        }
      ],
      "correct_answer": "B. Acute secretory diarrhea",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Acute secretory diarrhea</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Chronic diarrhea: Incorrect because Racecadotril is not used for chronic diarrhea conditions as its effects are more suited to acute cases.</li><li>\u2022 Option A. Chronic diarrhea:</li><li>\u2022 Incorrect</li><li>\u2022 Racecadotril</li><li>\u2022 not</li><li>\u2022 chronic diarrhea</li><li>\u2022 acute cases.</li><li>\u2022 Option C. Chronic constipation: Incorrect as Racecadotril's mechanism of reducing fluid secretion would be detrimental in constipation , potentially worsening the condition.</li><li>\u2022 Option C. Chronic constipation:</li><li>\u2022 Incorrect</li><li>\u2022 Racecadotril's</li><li>\u2022 reducing fluid secretion</li><li>\u2022 detrimental in</li><li>\u2022 constipation</li><li>\u2022 worsening the condition.</li><li>\u2022 Option D. Diabetic gastroparesis: Incorrect because Racecadotril does not affect gastric emptying or motility , which are the primary concerns in diabetic gastroparesis.</li><li>\u2022 Option D. Diabetic gastroparesis:</li><li>\u2022 Incorrect</li><li>\u2022 Racecadotril</li><li>\u2022 does not</li><li>\u2022 gastric emptying or motility</li><li>\u2022 diabetic gastroparesis.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Racecadotril is specifically used for acute secretory diarrhea due to its ability to reduce fluid secretion in the gut , thereby decreasing stool output without significantly affecting intestinal motility.</li><li>\u27a4 Racecadotril</li><li>\u27a4 used for acute secretory diarrhea</li><li>\u27a4 ability to reduce fluid secretion</li><li>\u27a4 gut</li><li>\u27a4 decreasing stool output</li><li>\u27a4 without</li><li>\u27a4 intestinal motility.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "de258949",
      "audio": ""
    },
    {
      "text": "Most important mechanism of action for antiemetic property of metoclopramide is?",
      "options": [
        {
          "label": "A",
          "text": "5-HT3 antagonist",
          "correct": false
        },
        {
          "label": "B",
          "text": "D2-antagonist",
          "correct": true
        },
        {
          "label": "C",
          "text": "5-HT4 agonist",
          "correct": false
        },
        {
          "label": "D",
          "text": "M3-antagonist",
          "correct": false
        }
      ],
      "correct_answer": "B. D2-antagonist",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/screenshot-2024-05-03-104212.png"
      ],
      "explanation": "<p><strong>Ans. B) D2-antagonist</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. 5-HT3 antagonist: Incorrect because while 5-HT3 antagonists are indeed used as antiemetics, metoclopramide does not act through this mechanism. Drugs like ondansetron are typical examples of 5-HT3 antagonists.</li><li>\u2022 Option A. 5-HT3 antagonist: Incorrect because while 5-HT3 antagonists are indeed used as antiemetics, metoclopramide does not act through this mechanism. Drugs like ondansetron are typical examples of 5-HT3 antagonists.</li><li>\u2022 Option C. 5-HT4 agonist: Incorrect as metoclopramide does have some agonistic action at 5-HT4 receptors which promotes gastric emptying, but this is not the primary mechanism responsible for its antiemetic effects.</li><li>\u2022 Option C. 5-HT4 agonist: Incorrect</li><li>\u2022 metoclopramide</li><li>\u2022 agonistic action at 5-HT4 receptors</li><li>\u2022 promotes</li><li>\u2022 gastric</li><li>\u2022 emptying,</li><li>\u2022 not</li><li>\u2022 antiemetic effects.</li><li>\u2022 Option D. M3-antagonist: Incorrect because metoclopramide does not function as an M3 muscarinic antagonist . Antimuscarinics like scopolamine work by this mechanism for their antiemetic effects, which is different from how metoclopramide operates.</li><li>\u2022 Option D. M3-antagonist: Incorrect</li><li>\u2022 metoclopramide does not</li><li>\u2022 M3 muscarinic antagonist</li><li>\u2022 Antimuscarinics</li><li>\u2022 scopolamine</li><li>\u2022 mechanism</li><li>\u2022 antiemetic effects,</li><li>\u2022 metoclopramide operates.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Anti-emetics</li><li>\u27a4 Anti-emetics</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5ed7b2cd",
      "audio": ""
    },
    {
      "text": "You are going on a trip to a hill station with a friend who developed nausea and vomiting while travelling in the hills previously. Which of the following measure can be taken to prevent such an episode this time?",
      "options": [
        {
          "label": "A",
          "text": "Diphenhydramine one hour before the trip",
          "correct": false
        },
        {
          "label": "B",
          "text": "Scopolamine patch one night before the trip",
          "correct": true
        },
        {
          "label": "C",
          "text": "Ranitidine one night and one hour before the trip",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pantoprazole-one hour before the trip",
          "correct": false
        }
      ],
      "correct_answer": "B. Scopolamine patch one night before the trip",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Scopolamine patch one night before the trip</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Diphenhydramine one hour before the trip: Incorrect as diphenhydramine, while also used to treat motion sickness due to its antihistaminic properties, is generally considered less effective than scopolamine. It also has sedative effects , which can be undesirable for some travelers.</li><li>\u2022 Option A. Diphenhydramine one hour before the trip:</li><li>\u2022 Incorrect</li><li>\u2022 diphenhydramine,</li><li>\u2022 used to treat motion sickness</li><li>\u2022 antihistaminic properties,</li><li>\u2022 less effective</li><li>\u2022 sedative effects</li><li>\u2022 undesirable</li><li>\u2022 some travelers.</li><li>\u2022 Option C. Ranitidine one night and one hour before the trip: Incorrect because Ranitidine is an H2 receptor antagonist primarily used for reducing gastric acid and does not have antiemetic properties effective against motion sickness.</li><li>\u2022 Option C. Ranitidine one night and one hour before the trip:</li><li>\u2022 Incorrect</li><li>\u2022 H2 receptor antagonist</li><li>\u2022 reducing gastric acid</li><li>\u2022 does not</li><li>\u2022 antiemetic</li><li>\u2022 motion sickness.</li><li>\u2022 Option D. Pantoprazole one hour before the trip: Incorrect as Pantoprazole , a proton pump inhibitor, reduces stomach acid production but does not prevent nausea and vomiting due to motion sickness.</li><li>\u2022 Option D. Pantoprazole one hour before the trip:</li><li>\u2022 Incorrect</li><li>\u2022 Pantoprazole</li><li>\u2022 proton pump inhibitor,</li><li>\u2022 reduces</li><li>\u2022 does not</li><li>\u2022 nausea and vomiting</li><li>\u2022 motion sickness.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Scopolamine patch is a very effective preventive measure against motion sickness due to its muscarinic antagonist properties and should be applied 12 hours before travel to ensure efficacy.</li><li>\u27a4 Scopolamine patch</li><li>\u27a4 very effective</li><li>\u27a4 against motion sickness</li><li>\u27a4 muscarinic antagonist properties</li><li>\u27a4 12 hours before travel</li><li>\u27a4 efficacy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b989ac94",
      "audio": ""
    },
    {
      "text": "On a trip, 4 hours after having lunch at a restaurant, your friend develops diarrhea, and had 5 loose stools. There are signs of minimal dehydration. What should be your management?",
      "options": [
        {
          "label": "A",
          "text": "Buy ORS and give after preparing according to instructions.",
          "correct": true
        },
        {
          "label": "B",
          "text": "ORS and antibiotics, both tinidazole and ofloxacin.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Give only ofloxacin because tinidazole is not required as Giardia will not cause diarrhea within 4 hours.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Go to a hospital as he needs to be shown immediately, as night is approaching.",
          "correct": false
        }
      ],
      "correct_answer": "A. Buy ORS and give after preparing according to instructions.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Buy ORS and give after preparing according to instructions</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. ORS and antibiotics, both tinidazole and ofloxacin: Incorrect because antibiotics are not recommended without a specific diagnosis that indicates a bacterial infection, and their unnecessary use can lead to resistance and other complications. Furthermore, antibiotics are not effective against viruses or non-bacterial agents that might cause diarrhea.</li><li>\u2022 Option B. ORS and antibiotics, both tinidazole and ofloxacin:</li><li>\u2022 Incorrect</li><li>\u2022 antibiotics</li><li>\u2022 not</li><li>\u2022 without</li><li>\u2022 specific</li><li>\u2022 diagnosis</li><li>\u2022 indicates a bacterial infection,</li><li>\u2022 unnecessary use</li><li>\u2022 resistance and other complications.</li><li>\u2022 antibiotics</li><li>\u2022 not effective against viruses</li><li>\u2022 non-bacterial agents</li><li>\u2022 diarrhea.</li><li>\u2022 Option C. Give only ofloxacin because tinidazole is not required as Giardia will not cause diarrhea within 4 hours: Incorrect as this assumes a specific diagnosis without evidence , and the use of antibiotics like ofloxacin should be guided by a medical professional following appropriate tests.</li><li>\u2022 Option C. Give only ofloxacin because tinidazole is not required as Giardia will not cause diarrhea within 4 hours:</li><li>\u2022 Incorrect</li><li>\u2022 specific diagnosis without evidence</li><li>\u2022 use of antibiotics</li><li>\u2022 ofloxacin</li><li>\u2022 guided by a medical professional following appropriate tests.</li><li>\u2022 Option D. Go to a hospital as he needs to be shown immediately, as night is approaching: Not necessary at this stage as the symptoms are mild and manageable with ORS. Hospital visits are advised if symptoms escalate or if there are signs of severe dehydration or other complications .</li><li>\u2022 Option D. Go to a hospital as he needs to be shown immediately, as night is approaching:</li><li>\u2022 Not</li><li>\u2022 symptoms are mild and manageable with ORS.</li><li>\u2022 Hospital visits</li><li>\u2022 symptoms escalate</li><li>\u2022 dehydration or other complications</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 ORS is the first line of management for mild cases of diarrhea with minimal dehydration . It's effective, safe, and does not contribute to antibiotic resistance.</li><li>\u27a4 ORS</li><li>\u27a4 first line of management for mild cases of diarrhea</li><li>\u27a4 minimal dehydration</li><li>\u27a4 effective, safe,</li><li>\u27a4 does not</li><li>\u27a4 antibiotic resistance.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c046975e",
      "audio": ""
    },
    {
      "text": "Which of the following is a Guanylate Cyclase C agonist used in irritable bowel syndrome?",
      "options": [
        {
          "label": "A",
          "text": "Lubiprostine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Linaclotide",
          "correct": true
        },
        {
          "label": "C",
          "text": "Tegaserod",
          "correct": false
        },
        {
          "label": "D",
          "text": "Methyl naltrexone",
          "correct": false
        }
      ],
      "correct_answer": "B. Linaclotide",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/screenshot-2024-05-03-105608.png"
      ],
      "explanation": "<p><strong>Ans. B) Linaclotide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Lubiprostone: Incorrect because Lubiprostone works by activating chloride channels rather than acting as a guanylate Cyclase-C agonist. It is used primarily for treating chronic idiopathic constipation and IBS-C but via a different mechanism.</li><li>\u2022 Option A. Lubiprostone:</li><li>\u2022 Incorrect</li><li>\u2022 Lubiprostone</li><li>\u2022 activating chloride channels</li><li>\u2022 acting as a guanylate</li><li>\u2022 Cyclase-C agonist.</li><li>\u2022 used</li><li>\u2022 treating chronic idiopathic constipation</li><li>\u2022 IBS-C</li><li>\u2022 Option C. Tegaserod: Incorrect as Tegaserod is a 5-HT4 receptor agonist, not a guanylate Cyclase-C agonist. It\u2019s used to treat IBS-C in women by enhancing peristaltic reflex and bowel motility.</li><li>\u2022 Option C. Tegaserod:</li><li>\u2022 Incorrect</li><li>\u2022 5-HT4 receptor agonist, not</li><li>\u2022 guanylate Cyclase-C agonist.</li><li>\u2022 used</li><li>\u2022 IBS-C</li><li>\u2022 enhancing peristaltic reflex and bowel motility.</li><li>\u2022 Option D. Methyl naltrexone: Incorrect because Methyl naltrexone is a peripheral opioid receptor antagonist used specifically for opioid-induced constipation , acting by blocking the effects of opioids in the gut without affecting the central nervous system.</li><li>\u2022 Option D. Methyl naltrexone:</li><li>\u2022 Incorrect</li><li>\u2022 Methyl naltrexone</li><li>\u2022 peripheral opioid receptor antagonist</li><li>\u2022 opioid-induced constipation</li><li>\u2022 blocking the effects of opioids</li><li>\u2022 without</li><li>\u2022 central nervous system.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fd4c0878",
      "audio": ""
    },
    {
      "text": "Lubiprostone is a?",
      "options": [
        {
          "label": "A",
          "text": "Chloride channel activator",
          "correct": true
        },
        {
          "label": "B",
          "text": "Chloride channel inhibitor",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sodium channel activator",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sodium channel inhibitor",
          "correct": false
        }
      ],
      "correct_answer": "A. Chloride channel activator",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/screenshot-2024-05-03-110054.png"
      ],
      "explanation": "<p><strong>Ans. A) Chloride channel activator</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Chloride channel inhibitor: Incorrect as Lubiprostone does the opposite by activating, not inhibiting, chloride channels.</li><li>\u2022 Option B. Chloride channel inhibitor:</li><li>\u2022 Incorrect</li><li>\u2022 Lubiprostone</li><li>\u2022 opposite by activating,</li><li>\u2022 not inhibiting,</li><li>\u2022 chloride channels.</li><li>\u2022 Option C. Sodium channel activator: Incorrect because Lubiprostone does not affect sodium channels ; its action is specific to chloride channels.</li><li>\u2022 Option C. Sodium channel activator:</li><li>\u2022 Incorrect</li><li>\u2022 Lubiprostone does not</li><li>\u2022 sodium channels</li><li>\u2022 specific to</li><li>\u2022 chloride channels.</li><li>\u2022 Option D. Sodium channel inhibitor: Incorrect as Lubiprostone has no activity on sodium channels , either as an activator or inhibitor.</li><li>\u2022 Option D. Sodium channel inhibitor:</li><li>\u2022 Incorrect</li><li>\u2022 Lubiprostone</li><li>\u2022 no activity</li><li>\u2022 sodium channels</li><li>\u2022 either as an activator or</li><li>\u2022 inhibitor.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3f756977",
      "audio": ""
    },
    {
      "text": "Which of the following is an antagonist of a peptide and is used to reduce chemotherapy induced nausea and vomiting?",
      "options": [
        {
          "label": "A",
          "text": "Atrial natriuretic peptide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Aprepitant",
          "correct": true
        },
        {
          "label": "C",
          "text": "Bradykinin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Enalapril",
          "correct": false
        }
      ],
      "correct_answer": "B. Aprepitant",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Aprepitant</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Atrial natriuretic peptide: Incorrect as this peptide is involved in the regulation of blood pressure and fluid balance, not in the treatment of nausea or vomiting.</li><li>\u2022 Option A. Atrial natriuretic peptide:</li><li>\u2022 Incorrect</li><li>\u2022 peptide</li><li>\u2022 regulation of blood pressure and fluid balance,</li><li>\u2022 not</li><li>\u2022 nausea or vomiting.</li><li>\u2022 Option C. Bradykinin: Incorrect because Bradykinin is a peptide that plays a role in inflammation and blood pressure regulation , not directly in the control of nausea or vomiting.</li><li>\u2022 Option C. Bradykinin:</li><li>\u2022 Incorrect</li><li>\u2022 Bradykinin is a peptide</li><li>\u2022 inflammation and blood pressure</li><li>\u2022 regulation</li><li>\u2022 not</li><li>\u2022 control of nausea or vomiting.</li><li>\u2022 Option D. Enalapril: Incorrect as Enalapril is an ACE inhibitor used primarily to treat high blood pressure and heart failure, and has no role in managing chemotherapy-induced nausea and vomiting.</li><li>\u2022 Option D. Enalapril:</li><li>\u2022 Incorrect</li><li>\u2022 Enalapril</li><li>\u2022 is</li><li>\u2022 ACE inhibitor</li><li>\u2022 high blood pressure</li><li>\u2022 heart failure,</li><li>\u2022 no</li><li>\u2022 chemotherapy-induced nausea and vomiting.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Aprepitant is an NK1 receptor antagonist used specifically to prevent chemotherapy-induced nausea and vomiting by blocking the action of substance P.</li><li>\u27a4 Aprepitant</li><li>\u27a4 NK1 receptor antagonist</li><li>\u27a4 prevent chemotherapy-induced nausea and vomiting</li><li>\u27a4 blocking the</li><li>\u27a4 action of substance P.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ade8e441",
      "audio": ""
    },
    {
      "text": "Drug used in irritable bowel syndrome with constipation is?",
      "options": [
        {
          "label": "A",
          "text": "Lubiprostone",
          "correct": true
        },
        {
          "label": "B",
          "text": "Loperamide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Alosetron",
          "correct": false
        },
        {
          "label": "D",
          "text": "Clonidine",
          "correct": false
        }
      ],
      "correct_answer": "A. Lubiprostone",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/screenshot-2024-05-03-111701.png"
      ],
      "explanation": "<p><strong>Ans. A) Lubiprostone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Loperamide: Incorrect because Loperamide is primarily an anti-diarrheal medication, used to treat irritable bowel syndrome with diarrhea (IBS-D) due to its action as a \u00b5-opioid receptor agonist, which decreases intestinal motility.</li><li>\u2022 Option B. Loperamide:</li><li>\u2022 Incorrect</li><li>\u2022 Loperamide</li><li>\u2022 anti-diarrheal medication,</li><li>\u2022 treat irritable bowel</li><li>\u2022 syndrome with diarrhea (IBS-D)</li><li>\u2022 \u00b5-opioid receptor agonist,</li><li>\u2022 decreases intestinal motility.</li><li>\u2022 Option C. Alosetron: Incorrect as Alosetron is a 5-HT3 receptor antagonist used specifically for IBS with predominant diarrhea (IBS-D), where it helps by reducing visceral pain and slowing colonic transit.</li><li>\u2022 Option C. Alosetron:</li><li>\u2022 Incorrect</li><li>\u2022 Alosetron is a 5-HT3 receptor antagonist</li><li>\u2022 IBS</li><li>\u2022 predominant diarrhea</li><li>\u2022 (IBS-D),</li><li>\u2022 reducing visceral pain</li><li>\u2022 slowing colonic transit.</li><li>\u2022 Option D. Clonidine: Incorrect because Clonidine is an alpha-2 agonist used mainly in the management of hypertension and not typically for BSI . It has some applications in diabetic diarrhea , but not in IBS with constipation.</li><li>\u2022 Option D. Clonidine:</li><li>\u2022 Incorrect</li><li>\u2022 Clonidine</li><li>\u2022 alpha-2 agonist</li><li>\u2022 management of hypertension</li><li>\u2022 not</li><li>\u2022 BSI</li><li>\u2022 diabetic diarrhea</li><li>\u2022 not</li><li>\u2022 IBS with constipation.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3d7a4e28",
      "audio": ""
    },
    {
      "text": "Which is not an osmotic laxative?",
      "options": [
        {
          "label": "A",
          "text": "Sorbitol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Magnesium",
          "correct": false
        },
        {
          "label": "C",
          "text": "Polyethylene glycol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bisacodyl",
          "correct": true
        }
      ],
      "correct_answer": "D. Bisacodyl",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/screenshot-2024-05-03-112100.png"
      ],
      "explanation": "<p><strong>Ans. D) Bisacodyl</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Sorbitol: Incorrect as Sorbitol is an osmotic laxative that works by drawing water into the large intestine, increasing the water content in stools , which makes them easier to pass.</li><li>\u2022 Option A. Sorbitol:</li><li>\u2022 Incorrect</li><li>\u2022 Sorbitol</li><li>\u2022 osmotic laxative</li><li>\u2022 drawing water into the large intestine,</li><li>\u2022 increasing</li><li>\u2022 water content in stools</li><li>\u2022 easier to pass.</li><li>\u2022 Option B. Magnesium (e.g., magnesium citrate): Incorrect because magnesium compounds are osmotic laxatives . They increase the amount of water in the intestines , primarily through osmosis, which softens the stool and naturally stimulates bowel movement.</li><li>\u2022 Option B. Magnesium (e.g., magnesium citrate):</li><li>\u2022 Incorrect</li><li>\u2022 magnesium compounds</li><li>\u2022 osmotic laxatives</li><li>\u2022 increase</li><li>\u2022 amount of water in the intestines</li><li>\u2022 osmosis,</li><li>\u2022 softens the stool</li><li>\u2022 naturally stimulates bowel movement.</li><li>\u2022 Option C. Polyethylene glycol: Incorrect as it is an osmotic laxative known for its ability to retain water in the stool, which results in softer stools and promotes regular bowel movements.</li><li>\u2022 Option C. Polyethylene glycol:</li><li>\u2022 Incorrect</li><li>\u2022 osmotic laxative</li><li>\u2022 ability to retain water in the stool,</li><li>\u2022 softer stools</li><li>\u2022 promotes regular bowel movements.</li><li>\u2022 Educational Objectiv:</li><li>\u2022 Educational Objectiv:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bfa87b88",
      "audio": ""
    },
    {
      "text": "Pirenzepine is used for:",
      "options": [
        {
          "label": "A",
          "text": "Gastric ulcer",
          "correct": true
        },
        {
          "label": "B",
          "text": "Glaucoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hypertension",
          "correct": false
        },
        {
          "label": "D",
          "text": "Congestive cardiac failure",
          "correct": false
        }
      ],
      "correct_answer": "A. Gastric ulcer",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Gastric ulcer</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Glaucoma : Incorrect as Pirenzepine is not used to treat glaucoma. While muscarinic antagonists can affect eye conditions, pirenzepine\u2019s specific action on gastric secretions does not extend to intraocular pressure control.</li><li>\u2022 Option B. Glaucoma</li><li>\u2022 : Incorrect</li><li>\u2022 Pirenzepine</li><li>\u2022 not</li><li>\u2022 treat glaucoma.</li><li>\u2022 muscarinic antagonists</li><li>\u2022 eye conditions, pirenzepine\u2019s</li><li>\u2022 gastric secretions does not</li><li>\u2022 intraocular pressure control.</li><li>\u2022 Option C. Hypertension: Incorrect because Pirenzepine does not play a role in the management of blood pressure. Its pharmacological effects are confined to the digestive system.</li><li>\u2022 Option C. Hypertension:</li><li>\u2022 Incorrect</li><li>\u2022 Pirenzepine does not</li><li>\u2022 blood pressure.</li><li>\u2022 pharmacological effects</li><li>\u2022 digestive system.</li><li>\u2022 Option D. Congestive cardiac failure: Incorrect as Pirenzepine is not indicated for heart conditions like congestive cardiac failure . Its primary mechanism of action does not influence cardiac function or fluid management.</li><li>\u2022 Option D. Congestive cardiac failure:</li><li>\u2022 Incorrect</li><li>\u2022 Pirenzepine</li><li>\u2022 not</li><li>\u2022 heart conditions</li><li>\u2022 congestive cardiac failure</li><li>\u2022 primary mechanism of action does not</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pirenzepine is utilized in the management of gastric and duodenal ulcers due to its ability to selectively block M1 muscarinic receptors in the stomach, reducing gastric acid secretion which is beneficial for treating peptic ulcers.</li><li>\u27a4 Pirenzepine</li><li>\u27a4 gastric and duodenal ulcers</li><li>\u27a4 its ability to selectively block M1 muscarinic receptors</li><li>\u27a4 reducing gastric acid secretion</li><li>\u27a4 beneficial</li><li>\u27a4 peptic ulcers.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c04e5b0e",
      "audio": ""
    },
    {
      "text": "Which of the following is the drug of choice for treatment of chemotherapy-induced vomiting?",
      "options": [
        {
          "label": "A",
          "text": "Granisetron",
          "correct": true
        },
        {
          "label": "B",
          "text": "Prazosin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Clonidine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Dimenhydrinate",
          "correct": false
        }
      ],
      "correct_answer": "A. Granisetron",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Granisetron</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Prazosin: Incorrect because Prazosin is an alpha-1 blocker used primarily for managing hypertension and benign prostatic hyperplasia, not for vomiting.</li><li>\u2022 Option B. Prazosin:</li><li>\u2022 Option C. Clonidine: Incorrect as Clonidine is an alpha-2 agonist, used mainly for hypertension, ADHD, and anxiety disorders, and does not have a primary role in controlling chemotherapy-induced vomiting.</li><li>\u2022 Option C. Clonidine:</li><li>\u2022 Option D. Dimenhydrinate: Incorrect because Dimenhydrinate, an antihistamine, is primarily used for motion sickness and vertigo. While it can treat nausea and vomiting, it is not the drug of choice for chemotherapy-induced vomiting.</li><li>\u2022 Option D. Dimenhydrinate:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Granisetron is the drug of choice for managing chemotherapy-induced vomiting due to its effective inhibition of 5-HT3 receptors, critical in blocking the emetic pathway triggered by chemotherapy</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "66c05d63",
      "audio": ""
    },
    {
      "text": "What is the mechanism of action of teduglutide in short bowel syndrome?",
      "options": [
        {
          "label": "A",
          "text": "GLP-2 analog",
          "correct": true
        },
        {
          "label": "B",
          "text": "5HT-1B/1D Agonist",
          "correct": false
        },
        {
          "label": "C",
          "text": "GLP-1 analogs",
          "correct": false
        },
        {
          "label": "D",
          "text": "C-peptide analogs",
          "correct": false
        }
      ],
      "correct_answer": "A. GLP-2 analog",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) GLP-2 analog</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. 5HT-1B/1D Agonist: Incorrect because 5HT-1B/1D agonists, such as triptans, are primarily used for migraine relief through vasoconstriction and inhibition of CGRP release, not for treating intestinal issues.</li><li>\u2022 Option B. 5HT-1B/1D Agonist:</li><li>\u2022 Option C. GLP-1 analogs: Incorrect as GLP-1 analogs like exenatide and liraglutide are used in diabetes management due to their effects on insulin secretion and appetite suppression, rather than intestinal growth or nutrient absorption.</li><li>\u2022 Option C. GLP-1 analogs:</li><li>\u2022 Option D. C-peptide analogs: Incorrect because C-peptide analogs relate to insulin processing and are not used for treating conditions like short bowel syndrome.</li><li>\u2022 Option D. C-peptide analogs:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Teduglutide acts as a GLP-2 analog, which is critical for promoting intestinal growth and enhancing the absorptive functions of the gut, making it effective in managing short bowel syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "81a3b0a7",
      "audio": ""
    },
    {
      "text": "A patient present with chronic diarrhea and is prescribed an anti-diarrheal medication. Which of the following drugs acts by inhibiting 5-HT and is used specifically for irritable bowel syndrome with diarrhea (IBS-D)?",
      "options": [
        {
          "label": "A",
          "text": "Alosetron",
          "correct": true
        },
        {
          "label": "B",
          "text": "Clozapine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tegaserod",
          "correct": false
        },
        {
          "label": "D",
          "text": "Mosapride",
          "correct": false
        }
      ],
      "correct_answer": "A. Alosetron",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Alosetron</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Clozapine: Incorrect because Clozapine is an atypical antipsychotic primarily used for the treatment of schizophrenia and is not used for treating diarrhea or IBS.</li><li>\u2022 Option B. Clozapine:</li><li>\u2022 Incorrect</li><li>\u2022 atypical antipsychotic</li><li>\u2022 schizophrenia and</li><li>\u2022 not</li><li>\u2022 treating diarrhea or IBS.</li><li>\u2022 Option C. Tegaserod: Incorrect as Tegaserod is a 5-HT4 receptor partial agonist, primarily used for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) , not diarrhea.</li><li>\u2022 Option C. Tegaserod:</li><li>\u2022 Incorrect</li><li>\u2022 Tegaserod</li><li>\u2022 5-HT4 receptor partial agonist,</li><li>\u2022 used for the treatment</li><li>\u2022 constipation-predominant irritable bowel syndrome (IBS-C)</li><li>\u2022 Option D. Mosapride: Incorrect because Mosapride is a 5-HT4 agonist used to enhance gastrointestinal motility , commonly prescribed for conditions like GERD and functional dyspepsia, but not specifically for IBS-D.</li><li>\u2022 Option D. Mosapride:</li><li>\u2022 Incorrect</li><li>\u2022 Mosapride is a 5-HT4 agonist</li><li>\u2022 gastrointestinal motility</li><li>\u2022 GERD</li><li>\u2022 functional dyspepsia,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Alosetron</li><li>\u27a4 Alosetron</li><li>\u27a4 It is approved for the treatment of diarrhea predominant lBS in women. It is more potent antagonist of the 5-HT3 receptor than ondansetron. It shows significant improvements in abdominal pain as well as stool frequency, consistency and urgency in lBS patients. It also diminishes visceral sensitivity and slow colonic transit. Its major adverse effect is high incidence of development of ischemic colitis.</li><li>\u27a4 It is approved for the treatment of diarrhea predominant lBS in women.</li><li>\u27a4 treatment of diarrhea predominant lBS in women.</li><li>\u27a4 It is more potent antagonist of the 5-HT3 receptor than ondansetron.</li><li>\u27a4 antagonist of the 5-HT3 receptor</li><li>\u27a4 It shows significant improvements in abdominal pain as well as stool frequency, consistency and urgency in lBS patients.</li><li>\u27a4 improvements</li><li>\u27a4 abdominal pain</li><li>\u27a4 stool frequency,</li><li>\u27a4 consistency</li><li>\u27a4 urgency</li><li>\u27a4 It also diminishes visceral sensitivity and slow colonic transit.</li><li>\u27a4 diminishes</li><li>\u27a4 visceral sensitivity</li><li>\u27a4 slow colonic transit.</li><li>\u27a4 Its major adverse effect is high incidence of development of ischemic colitis.</li><li>\u27a4 major adverse effect</li><li>\u27a4 high</li><li>\u27a4 ischemic colitis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c185604d",
      "audio": ""
    },
    {
      "text": "Identify the incorrect statement regarding proton pump inhibitors:",
      "options": [
        {
          "label": "A",
          "text": "Available as enteric coated tablets",
          "correct": false
        },
        {
          "label": "B",
          "text": "Acts from the luminal side of gastric parietal cells",
          "correct": true
        },
        {
          "label": "C",
          "text": "Inactive at neutral pH",
          "correct": false
        },
        {
          "label": "D",
          "text": "Should be taken on empty stomach",
          "correct": false
        }
      ],
      "correct_answer": "B. Acts from the luminal side of gastric parietal cells",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Acts from the luminal side of gastric parietal cells</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Available as enteric coated tablets: This statement is correct . All PPIs are administered orally in enteric coated form to protect them from molecular transformation in the acidic gastric juice.</li><li>\u2022 Option A. Available as enteric coated tablets:</li><li>\u2022 correct</li><li>\u2022 PPIs</li><li>\u2022 orally</li><li>\u2022 enteric coated form</li><li>\u2022 protect</li><li>\u2022 from molecular transformation in the acidic gastric juice.</li><li>\u2022 Option C. Inactive at neutral pH: This statement is correct. Omeprazole is inactive at neutral pH , but at pH less than 5, it rearranges to two charged cationic forms (a sulphenic acid and a sulphenamide configurations ) that react covalently with SH groups of the H+K+ATPase enzyme and inactivate it irreversibly.</li><li>\u2022 Option C. Inactive at neutral pH:</li><li>\u2022 correct.</li><li>\u2022 inactive</li><li>\u2022 neutral pH</li><li>\u2022 pH less than 5,</li><li>\u2022 two charged cationic forms</li><li>\u2022 sulphenic acid</li><li>\u2022 sulphenamide configurations</li><li>\u2022 covalently with SH groups</li><li>\u2022 H+K+ATPase enzyme</li><li>\u2022 inactivate it irreversibly.</li><li>\u2022 Option D. Should be taken on an empty stomach: This statement is correct. Bioavailability of a ll PPIs is reduced by food; they should be taken on an empty stomach, followed 1 hour later by a meal to activate the H+K+ ATPase and make it more susceptible to the PPI.</li><li>\u2022 Option D. Should be taken on an empty stomach:</li><li>\u2022 correct.</li><li>\u2022 Bioavailability</li><li>\u2022 ll PPIs is reduced</li><li>\u2022 food;</li><li>\u2022 empty stomach,</li><li>\u2022 1 hour later</li><li>\u2022 activate the H+K+ ATPase</li><li>\u2022 more susceptible to</li><li>\u2022 the PPI.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 :</li><li>\u27a4 Proton pump inhibitors should be administered on an empty stomach to ensure maximum absorption and effectiveness . This should be followed by a meal an hour later to enhance the activation of gastric acid pumps, making them more susceptible to inhibition by the drug.</li><li>\u27a4 Proton pump inhibitors</li><li>\u27a4 administered on an empty stomach</li><li>\u27a4 maximum absorption and effectiveness</li><li>\u27a4 a meal an hour later to enhance the activation of gastric acid pumps,</li><li>\u27a4 more susceptible</li><li>\u27a4 inhibition by the drug.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1d12d01c",
      "audio": ""
    },
    {
      "text": "Which of the following drugs are not included in triple drug regimen for H. pylori associated peptic ulcer disease?",
      "options": [
        {
          "label": "A",
          "text": "PPI",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amoxicillin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tetracycline",
          "correct": true
        },
        {
          "label": "D",
          "text": "Clarithromycin",
          "correct": false
        }
      ],
      "correct_answer": "C. Tetracycline",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/screenshot-2024-05-03-114045.png"
      ],
      "explanation": "<p><strong>Ans. C) Tetracycline</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. PPI: Incorrect because proton pump inhibitors (such as Lansoprazole) are a crucial component of the triple therapy regimen, aiding in reducing gastric acid secretion to create a less acidic environment which enhances the effectiveness of antibiotics .</li><li>\u2022 Option A. PPI:</li><li>\u2022 Incorrect</li><li>\u2022 proton pump inhibitors (such as Lansoprazole)</li><li>\u2022 triple therapy</li><li>\u2022 reducing gastric acid secretion</li><li>\u2022 less acidic environment</li><li>\u2022 effectiveness of antibiotics</li><li>\u2022 Option B. Amoxicillin: Incorrect as Amoxicillin is one of the antibiotics recommended in the triple therapy , working by inhibiting the cell wall synthesis of H. pylori bacteria.</li><li>\u2022 Option B. Amoxicillin:</li><li>\u2022 Incorrect</li><li>\u2022 one of the antibiotics</li><li>\u2022 triple therapy</li><li>\u2022 inhibiting the</li><li>\u2022 cell wall synthesis</li><li>\u2022 H. pylori bacteria.</li><li>\u2022 Option D. Clarithromycin: Incorrect because Clarithromycin is included in the regimen and works by inhibiting protein synthesis of H. pylori , effectively helping in its eradication.</li><li>\u2022 Option D. Clarithromycin:</li><li>\u2022 Incorrect</li><li>\u2022 Clarithromycin</li><li>\u2022 inhibiting protein synthesis of H. pylori</li><li>\u2022 helping</li><li>\u2022 eradication.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c000b36c",
      "audio": ""
    },
    {
      "text": "Which of the following best describes the rationale of prucalopride in management of constipation dominant IBS?",
      "options": [
        {
          "label": "A",
          "text": "5 HT3 antagonism resulting in decreased stimulation of extrinsic primary afferent neurons",
          "correct": false
        },
        {
          "label": "B",
          "text": "5 HT1P antagonism resulting in decreased stimulation of intrinsic primary afferent neurons",
          "correct": false
        },
        {
          "label": "C",
          "text": "5 HT4 agonism resulting in increased CGRP release and enhanced motility",
          "correct": true
        },
        {
          "label": "D",
          "text": "Stimulation of type 2 chloride channel in small intestine increasing the volume of luminal contents.",
          "correct": false
        }
      ],
      "correct_answer": "C. 5 HT4 agonism resulting in increased CGRP release and enhanced motility",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 5 HT4 agonism resulting in increased CGRP release and enhanced motility</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. 5 HT3 antagonism resulting in decreased stimulation of extrinsic primary afferent neurons: Incorrect as 5-HT3 antagonists are primarily used in the management of diarrhea-predominant IBS (IBS-D), where they help by reducing gut motility and fluid secretion.</li><li>\u2022 Option A. 5 HT3 antagonism resulting in decreased stimulation of extrinsic primary afferent neurons:</li><li>\u2022 Incorrect as 5-HT3</li><li>\u2022 antagonists</li><li>\u2022 diarrhea-predominant IBS (IBS-D),</li><li>\u2022 reducing gut motility</li><li>\u2022 and fluid secretion.</li><li>\u2022 Option B. 5 HT1P antagonism resulting in decreased stimulation of intrinsic primary afferent neurons: Incorrect because there is no recognized 5-HT1P receptor in current serotonin receptor classification relevant to IBS management.</li><li>\u2022 Option B. 5 HT1P antagonism resulting in decreased stimulation of intrinsic primary afferent neurons:</li><li>\u2022 Incorrect</li><li>\u2022 no</li><li>\u2022 5-HT1P receptor</li><li>\u2022 serotonin receptor</li><li>\u2022 IBS management.</li><li>\u2022 Option D. Stimulation of type 2 chloride channel in small intestine increasing the volume of luminal contents: Incorrect as this describes the action of lubiprostone , not prucalopride. Lubiprostone works by activating type 2 chloride channels , leading to increased intestinal fluid secretion and stool passage.</li><li>\u2022 Option D. Stimulation of type 2 chloride channel in small intestine increasing the volume of luminal contents:</li><li>\u2022 Incorrect</li><li>\u2022 action of lubiprostone</li><li>\u2022 Lubiprostone</li><li>\u2022 activating type 2 chloride channels</li><li>\u2022 increased intestinal fluid secretion and stool passage.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Prucalopride enhances gastrointestinal motility through 5-HT4 agonism, which increases neurotransmitter release, notably CGRP, promoting enhanced peristalsis and improving symptoms of constipation-dominant IBS.</li><li>\u27a4 Prucalopride</li><li>\u27a4 gastrointestinal motility through 5-HT4 agonism,</li><li>\u27a4 increases neurotransmitter</li><li>\u27a4 CGRP,</li><li>\u27a4 peristalsis</li><li>\u27a4 improving</li><li>\u27a4 constipation-dominant IBS.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "878340e8",
      "audio": ""
    },
    {
      "text": "A 27-year-old woman who is 34 weeks pregnant is on bed rest and visits her obstetrician. During the visit, she informs her physician that she has been experiencing mild constipation. Which of the following medications will most likely be recommended to her?",
      "options": [
        {
          "label": "A",
          "text": "Castor oil",
          "correct": false
        },
        {
          "label": "B",
          "text": "Docusate",
          "correct": true
        },
        {
          "label": "C",
          "text": "Mineral oil",
          "correct": false
        },
        {
          "label": "D",
          "text": "Loperamide",
          "correct": false
        }
      ],
      "correct_answer": "B. Docusate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Docusate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Castor oil: Incorrect because castor oil is generally not recommended during pregnancy . It can trigger uterine contractions , which may pose risks to the fetus.</li><li>\u2022 Option A. Castor oil:</li><li>\u2022 Incorrect</li><li>\u2022 castor oil</li><li>\u2022 not</li><li>\u2022 pregnancy</li><li>\u2022 trigger uterine</li><li>\u2022 contractions</li><li>\u2022 pose risks to the fetus.</li><li>\u2022 Option C. Mineral oil: Incorrect as mineral oil is also not recommended during pregnancy . It can decrease the absorption of fat- s oluble vitamins , which are crucial for fetal development.</li><li>\u2022 Option C. Mineral oil:</li><li>\u2022 Incorrect</li><li>\u2022 not</li><li>\u2022 pregnancy</li><li>\u2022 decrease the absorption of fat-</li><li>\u2022 oluble vitamins</li><li>\u2022 crucial for fetal development.</li><li>\u2022 Option D. Loperamide: Incorrect because loperamide is an anti-diarrheal medication, not a treatment for constipation. It works by slowing down gut movement, which would be counterproductive in the treatment of constipation.</li><li>\u2022 Option D. Loperamide:</li><li>\u2022 Incorrect</li><li>\u2022 loperamide</li><li>\u2022 anti-diarrheal medication, not</li><li>\u2022 constipation.</li><li>\u2022 slowing down gut movement,</li><li>\u2022 counterproductive</li><li>\u2022 constipation.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Docusate is commonly recommended for treating constipation in pregnant women due to its efficacy and safety profile . It helps soften stools without the risks associated with other laxatives like castor oil and mineral oil , which can adversely affect pregnancy.</li><li>\u27a4 Docusate</li><li>\u27a4 treating constipation</li><li>\u27a4 pregnant women</li><li>\u27a4 its efficacy and safety profile</li><li>\u27a4 helps</li><li>\u27a4 soften stools without</li><li>\u27a4 other laxatives like castor oil and mineral oil</li><li>\u27a4 pregnancy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "78a0c701",
      "audio": ""
    },
    {
      "text": "An elderly woman with a recent history of myocardial infarction is seeking a medication to help treat her occasional heartburn. She is currently taking several medications, including aspirin, clopidogrel, simvastatin, metoprolol, and lisinopril. Which of the following choices should be avoided in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Calcium citrate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Famotidine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Omeprazole",
          "correct": true
        },
        {
          "label": "D",
          "text": "Ranitidine",
          "correct": false
        }
      ],
      "correct_answer": "C. Omeprazole",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Omeprazole</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Calcium citrate: This option is considered safe for treating heartburn and does not interact adversely with clopidogrel or the other medications the patient is taking.</li><li>\u2022 Option A. Calcium citrate:</li><li>\u2022 safe for treating heartburn</li><li>\u2022 does not interact</li><li>\u2022 clopidogrel or</li><li>\u2022 other medications</li><li>\u2022 Option B. Famotidine: Famotidine is an H2-receptor antagonist and does not interfere with the CYP2C19 enzyme, making it a safe option for this patient.</li><li>\u2022 Option B. Famotidine:</li><li>\u2022 H2-receptor antagonist</li><li>\u2022 does not</li><li>\u2022 CYP2C19 enzyme,</li><li>\u2022 safe</li><li>\u2022 Option D. Ranitidine: Although ranitidine is also an H2-receptor antagonist, it has been found to be safe in terms of not significantly affecting the metabolism of clopidogrel like omeprazole does. However, due to other concerns such as potential NDMA contamination, ranitidine has been recalled in many markets.</li><li>\u2022 Option D. Ranitidine:</li><li>\u2022 H2-receptor antagonist,</li><li>\u2022 safe in terms</li><li>\u2022 metabolism of clopidogrel like omeprazole does.</li><li>\u2022 potential NDMA</li><li>\u2022 contamination,</li><li>\u2022 ranitidine</li><li>\u2022 recalled in many markets.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While treating heartburn in patients on multiple medications, especially those on clopidogrel post-myocardial infarction, it is important to avoid proton pump inhibitors like omeprazole due to their potential to inhibit CYP2C19 and reduce the effectiveness of clopidogrel , thereby increasing the risk of cardiovascular events.</li><li>\u27a4 heartburn in patients</li><li>\u27a4 multiple medications,</li><li>\u27a4 clopidogrel post-myocardial infarction,</li><li>\u27a4 avoid proton pump inhibitors</li><li>\u27a4 omeprazole</li><li>\u27a4 inhibit CYP2C19</li><li>\u27a4 reduce</li><li>\u27a4 clopidogrel</li><li>\u27a4 increasing the risk of cardiovascular events.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1effbc4c",
      "audio": ""
    },
    {
      "text": "In emergency department, an intern gave an anti-emetic drug to a patient and the patient then developed abnormal posture and torticollis. Most likely drug is?",
      "options": [
        {
          "label": "A",
          "text": "Ondansetron",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dexamethasone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Metoclopramide",
          "correct": true
        },
        {
          "label": "D",
          "text": "Dronabinol",
          "correct": false
        }
      ],
      "correct_answer": "C. Metoclopramide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Metoclopramide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Ondansetron: Incorrect because Ondansetron is a 5-HT3 receptor antagonist that is generally used to prevent nausea and vomiting associated with cancer chemotherapy and surgery and does not typically cause extrapyramidal side effects.</li><li>\u2022 Option A. Ondansetron:</li><li>\u2022 Incorrect</li><li>\u2022 Ondansetron is a 5-HT3 receptor antagonist</li><li>\u2022 used to prevent nausea and</li><li>\u2022 vomiting</li><li>\u2022 cancer chemotherapy and surgery</li><li>\u2022 does not</li><li>\u2022 extrapyramidal side effects.</li><li>\u2022 Option B. Dexamethasone : Incorrect as Dexamethasone is a corticosteroid used as an antiemetic in chemotherapy s ettings. It works by reducing inflammation and does not cause extrapyramidal symptoms.</li><li>\u2022 Option B. Dexamethasone</li><li>\u2022 Incorrect</li><li>\u2022 corticosteroid</li><li>\u2022 antiemetic in chemotherapy s</li><li>\u2022 reducing inflammation</li><li>\u2022 does not</li><li>\u2022 extrapyramidal symptoms.</li><li>\u2022 Option D. Dronabinol: Incorrect because Dronabinol is a cannabinoid receptor agonist used to treat nausea and vomiting caused by chemotherapy and to stimulate appetite. Its side effects may include dysphoria, dizziness, and ataxia but not dystonia or torticollis.</li><li>\u2022 Option D. Dronabinol:</li><li>\u2022 Incorrect</li><li>\u2022 Dronabinol</li><li>\u2022 cannabinoid receptor agonist</li><li>\u2022 nausea and vomiting</li><li>\u2022 chemotherapy</li><li>\u2022 stimulate appetite.</li><li>\u2022 dysphoria, dizziness, and ataxia</li><li>\u2022 not dystonia or torticollis.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Metoclopramide , while effective as an antiemetic and for promoting gastric motility , can cause extrapyramidal symptoms such as dystonia due to its antagonistic effects on dopamine D2 receptors . These effects are important to monitor, especially in emergency settings.</li><li>\u27a4 Metoclopramide</li><li>\u27a4 antiemetic and for promoting gastric motility</li><li>\u27a4 extrapyramidal</li><li>\u27a4 dystonia</li><li>\u27a4 antagonistic effects</li><li>\u27a4 dopamine</li><li>\u27a4 D2 receptors</li><li>\u27a4 important to monitor,</li><li>\u27a4 emergency</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "68a9d0d1",
      "audio": ""
    },
    {
      "text": "Which one of the following is the CFTR channel inhibitor?",
      "options": [
        {
          "label": "A",
          "text": "Linaclotide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Crofelemer",
          "correct": true
        },
        {
          "label": "C",
          "text": "Alvimopan",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prucalopride",
          "correct": false
        }
      ],
      "correct_answer": "B. Crofelemer",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Crofelemer</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A.  Linaclotide: Linaclotide is a guanylate cyclase-C agonist used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation . It works by increasing the secretion of chloride and bicarbonate ions in the intestine, leading to increased fluid secretion and accelerated gastrointestinal transit time.</li><li>\u2022 Option A.  Linaclotide:</li><li>\u2022 guanylate cyclase-C agonist</li><li>\u2022 irritable bowel syndrome</li><li>\u2022 constipation</li><li>\u2022 chronic idiopathic constipation</li><li>\u2022 increasing the secretion of chloride and bicarbonate ions</li><li>\u2022 increased fluid secretion</li><li>\u2022 accelerated gastrointestinal transit time.</li><li>\u2022 Option C. Alvimopan: Alvimopan is a peripherally acting mu-opioid receptor antagonist used to treat postoperative ileus. It works by blocking the action of opioids on the mu-opioid receptor in the gastrointestinal tract, which can reduce gastrointestinal motility and cause constipation.</li><li>\u2022 Option C. Alvimopan:</li><li>\u2022 mu-opioid receptor antagonist</li><li>\u2022 postoperative ileus.</li><li>\u2022 blocking the action of opioids</li><li>\u2022 mu-opioid receptor</li><li>\u2022 gastrointestinal tract,</li><li>\u2022 reduce gastrointestinal motility</li><li>\u2022 constipation.</li><li>\u2022 Option D. Prucalopride : Prucalopride is a selective serotonin type 4 (5-HT4) receptor agonist used in the treatment of chronic idiopathic constipation . It works by stimulating colonic motility and accelerating gastrointestinal transit time, which can lead to increased bowel movements.</li><li>\u2022 Option D. Prucalopride</li><li>\u2022 selective serotonin type 4 (5-HT4) receptor agonist</li><li>\u2022 chronic</li><li>\u2022 idiopathic constipation</li><li>\u2022 stimulating colonic motility</li><li>\u2022 accelerating gastrointestinal transit time,</li><li>\u2022 increased bowel movements.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Crofelemer is unique as a CFTR channel inhibitor, making it effective in treating diarrhea by reducing chloride and water secretion into the intestines , which contrasts with other options that primarily affect motility or opioid receptor antagonism.</li><li>\u27a4 Crofelemer</li><li>\u27a4 CFTR channel inhibitor,</li><li>\u27a4 treating diarrhea by reducing chloride and water secretion</li><li>\u27a4 intestines</li><li>\u27a4 contrasts</li><li>\u27a4 other options</li><li>\u27a4 motility or opioid receptor antagonism.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "502606cb",
      "audio": ""
    },
    {
      "text": "Selective M1 antagonist used in Gastric ulcer is?",
      "options": [
        {
          "label": "A",
          "text": "Omeprazole",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ranitidine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pirenzepine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Misoprostol",
          "correct": false
        }
      ],
      "correct_answer": "C. Pirenzepine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/screenshot-2024-05-03-120507.png"
      ],
      "explanation": "<p><strong>Ans. C) Pirenzepine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Omeprazole: Incorrect because Omeprazole is a proton pump inhibitor (PPI) that works by irreversibly blocking the hydrogen/potassium ATPase enzyme in the stomach , leading to a significant reduction in gastric acid secretion. It does not act as a muscarinic antagonist.</li><li>\u2022 Option A. Omeprazole:</li><li>\u2022 Incorrect</li><li>\u2022 Omeprazole is a proton pump inhibitor (PPI)</li><li>\u2022 irreversibly blocking</li><li>\u2022 hydrogen/potassium ATPase enzyme in the stomach</li><li>\u2022 reduction in gastric acid secretion.</li><li>\u2022 does not</li><li>\u2022 muscarinic antagonist.</li><li>\u2022 Option B. Ranitidine: Incorrect as Ranitidine is an H2 blocker that competitively inhibits histamine at H2 receptors on parietal cells, thereby decreasing gastric acid secretion . It is not a muscarinic antagonist.</li><li>\u2022 Option B. Ranitidine:</li><li>\u2022 Incorrect</li><li>\u2022 H2 blocker</li><li>\u2022 competitively inhibits</li><li>\u2022 histamine</li><li>\u2022 H2 receptors on parietal cells,</li><li>\u2022 decreasing gastric acid secretion</li><li>\u2022 Option D. Misoprostol: Incorrect because Misoprostol is a mucosal protectant used primarily to prevent gastric ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs) by mimicking the action of prostaglandins . It does not involve muscarinic receptor antagonism.</li><li>\u2022 Option D. Misoprostol:</li><li>\u2022 Incorrect</li><li>\u2022 mucosal protectant</li><li>\u2022 prevent gastric ulcers</li><li>\u2022 nonsteroidal anti-inflammatory drugs (NSAIDs)</li><li>\u2022 mimicking</li><li>\u2022 prostaglandins</li><li>\u2022 does not</li><li>\u2022 muscarinic receptor</li><li>\u2022 antagonism.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "608a307d",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman has been complaining of chronic constipation for several months. She has been taking a laxative regularly for relief. She underwent colonoscopy which reveals the presence of dark black discoloration of colon (melanosis coli). Which of the following medications is most likely causing this discoloration of the colon?",
      "options": [
        {
          "label": "A",
          "text": "Liquid paraffin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Senna",
          "correct": true
        },
        {
          "label": "C",
          "text": "Bisacodyl",
          "correct": false
        },
        {
          "label": "D",
          "text": "Psyllium",
          "correct": false
        }
      ],
      "correct_answer": "B. Senna",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Senna</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Liquid paraffin: Incorrect because liquid paraffin, a lubricant laxative , does not cause melanosis coli. It works by coating the stool and the gut, easing the passage of stool without affecting the mucosa's pigmentation.</li><li>\u2022 Option A. Liquid paraffin:</li><li>\u2022 Incorrect</li><li>\u2022 liquid paraffin,</li><li>\u2022 lubricant laxative</li><li>\u2022 does not</li><li>\u2022 melanosis coli.</li><li>\u2022 stool and the gut,</li><li>\u2022 easing</li><li>\u2022 passage of stool</li><li>\u2022 Option C. Bisacodyl: Incorrect as bisacodyl, a stimulant laxative, primarily induces bowel movements by stimulating nerve endings in the colon wall but is not linked to the development of melanosis coli.</li><li>\u2022 Option C. Bisacodyl:</li><li>\u2022 Incorrect</li><li>\u2022 bisacodyl,</li><li>\u2022 stimulant laxative,</li><li>\u2022 bowel movements by stimulating nerve endings</li><li>\u2022 colon wall</li><li>\u2022 not</li><li>\u2022 development of melanosis coli.</li><li>\u2022 Option D. Psyllium: Incorrect because psyllium , a bulk-forming laxative , absorbs water in the intestine to form a viscous liquid that promotes bowel movements. It does not cause discoloration of the colon's mucosa.</li><li>\u2022 Option D. Psyllium:</li><li>\u2022 Incorrect</li><li>\u2022 psyllium</li><li>\u2022 bulk-forming laxative</li><li>\u2022 absorbs water</li><li>\u2022 intestine to form a viscous liquid</li><li>\u2022 promotes bowel movements.</li><li>\u2022 does not</li><li>\u2022 discoloration of the colon's mucosa.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Senna , an anthraquinone-containing laxative, is associated with melanosis coli, a benign condition marked by dark pigmentation of the colon. This condition highlights the need to reassess and possibly adjust chronic constipation management.</li><li>\u27a4 Senna</li><li>\u27a4 anthraquinone-containing laxative,</li><li>\u27a4 melanosis coli,</li><li>\u27a4 benign</li><li>\u27a4 dark pigmentation of</li><li>\u27a4 colon.</li><li>\u27a4 reassess and possibly</li><li>\u27a4 chronic constipation management.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2d387da4",
      "audio": ""
    },
    {
      "text": "All of the following drugs are used for constipation dominant IBS except?",
      "options": [
        {
          "label": "A",
          "text": "Lubiprostone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Linaclotide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Alosetron",
          "correct": true
        },
        {
          "label": "D",
          "text": "Prucalopride",
          "correct": false
        }
      ],
      "correct_answer": "C. Alosetron",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/screenshot-2024-05-03-121117.png"
      ],
      "explanation": "<p><strong>Ans. C) Alosetron</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Lubiprostone: Incorrect because Lubiprostone is indeed used for constipation-dominant IBS. It is a chloride channel activator that increases fluid secretion in the intestine , which facilitates stool passage and alleviates constipation.</li><li>\u2022 Option A. Lubiprostone:</li><li>\u2022 Incorrect</li><li>\u2022 constipation-dominant IBS.</li><li>\u2022 chloride channel</li><li>\u2022 activator</li><li>\u2022 increases fluid secretion in the intestine</li><li>\u2022 facilitates stool passage and alleviates constipation.</li><li>\u2022 Option B. Linaclotide: Incorrect as Linaclotide is used for IBS-C . It is a guanylate cyclase-C agonist that increases both chloride and bicarbonate secretion into the intestine , enhancing fluid secretion and improving bowel movement.</li><li>\u2022 Option B. Linaclotide:</li><li>\u2022 Incorrect</li><li>\u2022 used for IBS-C</li><li>\u2022 guanylate cyclase-C agonist</li><li>\u2022 increases both chloride and</li><li>\u2022 bicarbonate secretion</li><li>\u2022 intestine</li><li>\u2022 fluid secretion and improving bowel movement.</li><li>\u2022 Option D. Prucalopride: Incorrect because Prucalopride is a 5-HT4 agonist that enhances gastrointestinal motility, making it suitable for treating IBS-C by accelerating transit time through the colon.</li><li>\u2022 Option D. Prucalopride:</li><li>\u2022 Incorrect</li><li>\u2022 Prucalopride is a 5-HT4 agonist</li><li>\u2022 gastrointestinal motility,</li><li>\u2022 IBS-C by accelerating transit</li><li>\u2022 colon.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Drugs Used in IBS</li><li>\u27a4 Drugs Used in IBS</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ce35f685",
      "audio": ""
    },
    {
      "text": "Anti-Platelet therapy is usually given for patients with stroke, MI and peripheral vascular disease. PPIs are frequently administered along with these drugs to prevent the risk of increased gastrointestinal erosions and bleeding. The interaction between clopidogrel and PPI has recently been given much attention due to its clinical significance. The metabolizing enzyme common to these two drugs is?",
      "options": [
        {
          "label": "A",
          "text": "CYP2C10",
          "correct": false
        },
        {
          "label": "B",
          "text": "CYPA2",
          "correct": false
        },
        {
          "label": "C",
          "text": "CYP2C19",
          "correct": true
        },
        {
          "label": "D",
          "text": "CYP2C20",
          "correct": false
        }
      ],
      "correct_answer": "C. CYP2C19",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) CYP2C19</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. CYP2C10: Incorrect as CYP2C10 is not a recognized enzyme in the cytochrome P450 family that is relevant to clopidogrel or PPI metabolism.</li><li>\u2022 Option A. CYP2C10:</li><li>\u2022 Incorrect</li><li>\u2022 CYP2C10</li><li>\u2022 not</li><li>\u2022 cytochrome P450</li><li>\u2022 relevant to clopidogrel or PPI metabolism.</li><li>\u2022 Option B. CYPA2: Incorrect because CYPA2 does not exist. The cytochrome P450 enzymes are typically designated with a format starting with CYP followed by numbers and letters (e.g., CYP2C19).</li><li>\u2022 Option B. CYPA2:</li><li>\u2022 Incorrect</li><li>\u2022 CYPA2 does not</li><li>\u2022 cytochrome P450 enzymes</li><li>\u2022 format</li><li>\u2022 CYP</li><li>\u2022 numbers and letters (e.g., CYP2C19).</li><li>\u2022 Option D. CYP2C20: Incorrect as CYP2C20 is not an established member of the cytochrome P450 enzyme family involved in the metabolism of clopidogrel or PPIs.</li><li>\u2022 Option D. CYP2C20:</li><li>\u2022 Incorrect</li><li>\u2022 CYP2C20</li><li>\u2022 not</li><li>\u2022 cytochrome P450 enzyme family</li><li>\u2022 clopidogrel or PPIs.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 CYP2C19 is the key enzyme involved in the activation of clopidogrel and that certain PPIs, such as omeprazole and esomeprazole , can inhibit this enzyme , potentially reducing the antiplatelet activity of clopidogrel .</li><li>\u27a4 CYP2C19</li><li>\u27a4 activation of clopidogrel</li><li>\u27a4 PPIs, such as omeprazole and esomeprazole</li><li>\u27a4 inhibit this enzyme</li><li>\u27a4 reducing the antiplatelet activity of clopidogrel</li><li>\u27a4 Awareness of this interaction is crucial when managing patients who require both antiplatelet and gastric protective therapies.</li><li>\u27a4 Awareness of this interaction</li><li>\u27a4 crucial</li><li>\u27a4 require both antiplatelet and gastric protective therapies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c754c6d4",
      "audio": ""
    },
    {
      "text": "Which of the following is not a prokinetic drug?",
      "options": [
        {
          "label": "A",
          "text": "5HT4-agonist",
          "correct": false
        },
        {
          "label": "B",
          "text": "D2 blocker",
          "correct": false
        },
        {
          "label": "C",
          "text": "Macrolides",
          "correct": false
        },
        {
          "label": "D",
          "text": "Diphenoxymethane",
          "correct": true
        }
      ],
      "correct_answer": "D. Diphenoxymethane",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/screenshot-2024-05-03-121706.png"
      ],
      "explanation": "<p><strong>Ans. D) Diphenoxymethane</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. 5HT4-agonist: Incorrect as 5HT4-agonists , such as mosapride, tegaserod, and prucalopride, are indeed prokinetic drugs. They stimulate peristalsis and increase gastric emptying by acting on the 5HT4 receptors in the gastrointestinal tract.</li><li>\u2022 Option A. 5HT4-agonist:</li><li>\u2022 Incorrect</li><li>\u2022 5HT4-agonists</li><li>\u2022 mosapride, tegaserod, and prucalopride,</li><li>\u2022 prokinetic drugs.</li><li>\u2022 stimulate peristalsis</li><li>\u2022 increase gastric emptying</li><li>\u2022 5HT4 receptors in the gastrointestinal tract.</li><li>\u2022 Option B. D2 blocker: Incorrect because D2 blockers like metoclopramide and domperidone are used as prokinetic drugs due to their ability to enhance gastrointestinal motility by blocking dopamine receptors, which promotes gastric emptying and decreases nausea and vomiting.</li><li>\u2022 Option B. D2 blocker:</li><li>\u2022 Incorrect</li><li>\u2022 D2 blockers</li><li>\u2022 metoclopramide and domperidone</li><li>\u2022 prokinetic drugs</li><li>\u2022 ability to enhance gastrointestinal motility</li><li>\u2022 blocking dopamine receptors,</li><li>\u2022 gastric emptying</li><li>\u2022 decreases</li><li>\u2022 nausea and vomiting.</li><li>\u2022 Option C. Macrolides: Incorrect as certain macrolides, such as erythromycin , act as motilin receptor agonists in the gut and are used for their prokinetic effects to stimulate gastric motility.</li><li>\u2022 Option C. Macrolides:</li><li>\u2022 Incorrect</li><li>\u2022 erythromycin</li><li>\u2022 motilin receptor agonists</li><li>\u2022 prokinetic effects to stimulate gastric motility.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b1b73591",
      "audio": ""
    }
  ]
}